Literature DB >> 25190262

Effectiveness research in the evolving HCV landscape.

Lisa I Backus1, Pamela S Belperio.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25190262     DOI： 10.1007/s10620-014-3345-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  18 in total

Review 1.  Comparative effectiveness research: Relevance and applications to pharmacy.

Authors:  Glen T Schumock; A Simon Pickard
Journal:  Am J Health Syst Pharm       Date:  2009-07-15       Impact factor: 2.637

2.  Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors:  Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

3.  Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Michael Manns; Patrick Marcellin; Fred Poordad; Evaldo Stanislau Affonso de Araujo; Maria Buti; Yves Horsmans; Ewa Janczewska; Federico Villamil; Jane Scott; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Lancet       Date:  2014-06-04       Impact factor: 79.321

4.  Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.

Authors:  Benjamin Maasoumy; Kerstin Port; Katja Deterding; Christoph Höner Zu Siederdissen; Antoaneta A Markova; Magdalena Rogalska-Taranta; Michael P Manns; Heiner Wedemeyer; Markus Cornberg
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-08       Impact factor: 2.566

5.  Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.

Authors:  Pamela S Belperio; Elizabeth W Hwang; I Chun Thomas; Larry A Mole; Ramsey C Cheung; Lisa I Backus
Journal:  Clin Gastroenterol Hepatol       Date:  2013-03-21       Impact factor: 11.382

6.  Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.

Authors:  George N Ioannou; Lauren A Beste; Pamela K Green
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-17       Impact factor: 11.382

7.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Authors:  Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

8.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

9.  Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

Authors:  Christophe Hézode; Helene Fontaine; Celine Dorival; Fabien Zoulim; Dominique Larrey; Valerie Canva; Victor De Ledinghen; Thierry Poynard; Didier Samuel; Marc Bourliere; Laurent Alric; Jean-Jacques Raabe; Jean-Pierre Zarski; Patrick Marcellin; Ghassan Riachi; Pierre-Henri Bernard; Veronique Loustaud-Ratti; Olivier Chazouilleres; Armand Abergel; Dominique Guyader; Sophie Metivier; Albert Tran; Vincent Di Martino; Xavier Causse; Thong Dao; Damien Lucidarme; Isabelle Portal; Patrice Cacoub; Jerome Gournay; Veronique Grando-Lemaire; Patrick Hillon; Pierre Attali; Thierry Fontanges; Isabelle Rosa; Ventzislava Petrov-Sanchez; Yoann Barthe; Jean-Michel Pawlotsky; Stanislas Pol; Fabrice Carrat; Jean-Pierre Bronowicki
Journal:  Gastroenterology       Date:  2014-04-03       Impact factor: 22.682

10.  Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.

Authors:  Malte H Wehmeyer; Friederike Eißing; Sabine Jordan; Claudia Röder; Annette Hennigs; Olaf Degen; Anja Hüfner; Sandra Hertling; Stefan Schmiedel; Martina Sterneck; Jan van Lunzen; Ansgar W Lohse; Julian Schulze zur Wiesch; Stefan Lüth
Journal:  BMC Gastroenterol       Date:  2014-05-05       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.